Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
Jordi RealBogdan VlachoEmilio OrtegaJoan Antoni VallésManel Mata-CasesEsmeralda CastelblancoEric T WittbrodtPeter FeniciMikhail KosiborodDídac MauricioJosep FranchPublished in: Cardiovascular diabetology (2021)
In this large, retrospective observational study of patients with T2DM from a Catalonia, initiation of SGLT-2i was associated with lower risk of mortality, as well as heart failure and CKD.